Project Name: Novartis Re-imagining Care Pathways Collaborative Working Project (“NRCP CWP”) for the Neuroendocrine Tumours Service

Project Summary:

The Reimagining Care Pathways CWP is a service offered by Novartis, which comprises a series of workshops, with the aim of providing pathway mapping support to the CW Partner to: 

  1. Identify potential service inefficiencies and service bottlenecks. Optimisation of these areas by the CWP will lead to improved patient care, improve efficiency and service effectiveness.
  2. Address the challenges in the delivery of patient care. 

The programme facilitates area teams (Trust or ICS) to identify areas for optimisation within their Neuroendocrine Tumour service. The programme will be carried out in a number of different institutions. The service is facilitated by the Novartis Service Development Manager (SDM) Team. 

Planned Milestones:

Milestone 1: Agree on the scope of the NRCP CWP 

Milestone 2: Mapping the Pathway; 1-1 interviews 

Milestone 3: Mapping the pathway workshop 

Milestone 4: Feedback/consultation with NHS post workshop

Expected Benefits:

ANTICIPATED BENEFITS FOR PATIENTS

  • Improvement of clinical pathways which may result in potentially fewer visits and shorter waiting times due to a more efficient clinical pathway 
  • Faster and more equitable access to the complete range of NICE approved treatment options. 
  • Quality care improvements aligned to established best practices 

ANTICIPATED BENEFITS FOR THE ORGANISATION(S) 

  • Improved understanding of the current service pathway, and associated efficiencies and inefficiencies. Potential to lead to solutions which could allow the CW Partner’s organisation to enhance both patient experience and outcomes.

ANTICIPATED BENEFITS FOR NOVARTIS 

  • Understanding of possible opportunities to partner with the CW Partner to enhance patient outcomes and experience. Better understanding of patients,’ carers and customers’ needs, which may inform future service offerings, and synergies between needs of the customer and value of Novartis offerings.

Start Date & Duration: May 2025, 14 weeks

FA-11392276 | May 2025